(Reuters) -Metsera, an obesity drug developer, said on Friday that it has entered into an amended merger agreement with Pfizer, in which the New York-based company will acquire Metsera for up to $86.25 per share.
Metsera’s board has recommended that its shareholders “approve the adoption of the amended Pfizer merger agreement and approve the merger with Pfizer.”
(Reporting by Rishabh Jaiswal in Bengaluru; Editing by Leslie Adler and Thomas Derpinghaus)
